GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CERo Therapeutics Holdings Inc (NAS:CERO) » Definitions » Revenue per Share

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Revenue per Share : $ (TTM As of Dec. 2022)


View and export this data going back to 2024. Start your Free Trial

What is CERo Therapeutics Holdings Revenue per Share?

CERo Therapeutics Holdings's revenue per share for the six months ended in Dec. 2022 was $0.00. CERo Therapeutics Holdings does not have enough years/quarters to calculate the revenue per share for the trailing twelve months (TTM) ended in Dec. 2022.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for CERo Therapeutics Holdings's Revenue per Share or its related term are showing as below:

CERO's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.6
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

CERo Therapeutics Holdings Revenue per Share Historical Data

The historical data trend for CERo Therapeutics Holdings's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CERo Therapeutics Holdings Revenue per Share Chart

CERo Therapeutics Holdings Annual Data
Trend Dec21 Dec22
Revenue per Share
- -

CERo Therapeutics Holdings Semi-Annual Data
Dec21 Dec22
Revenue per Share - -

Competitive Comparison of CERo Therapeutics Holdings's Revenue per Share

For the Biotechnology subindustry, CERo Therapeutics Holdings's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CERo Therapeutics Holdings's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CERo Therapeutics Holdings's PS Ratio distribution charts can be found below:

* The bar in red indicates where CERo Therapeutics Holdings's PS Ratio falls into.



CERo Therapeutics Holdings Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

CERo Therapeutics Holdings's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )=Revenue (A: Dec. 2022 )/Shares Outstanding (Diluted Average) (A: Dec. 2022 )
=0/10.293
=0.00

CERo Therapeutics Holdings's Revenue Per Share for the quarter that ended in Dec. 2022 is calculated as

Revenue Per Share (Q: Dec. 2022 )=Revenue (Q: Dec. 2022 )/Shares Outstanding (Diluted Average) (Q: Dec. 2022 )
=0/10.293
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CERo Therapeutics Holdings  (NAS:CERO) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


CERo Therapeutics Holdings Revenue per Share Related Terms

Thank you for viewing the detailed overview of CERo Therapeutics Holdings's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


CERo Therapeutics Holdings (CERo Therapeutics Holdings) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
201 Haskings Way, Suite 230, San Francisco, CA, USA, 94080
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

CERo Therapeutics Holdings (CERo Therapeutics Holdings) Headlines